Semaglutide liver fat quantification — what worked for you?

VanRx_Mike said:

The liver data is among the strongest non-weight findings in the class.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

Worth separating that from liver and MASH, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

AmyNC_wife said:

Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.

That reframing is the part I needed. Adding it to my notes with a link back to this thread.

VanRx_Mike said:

The liver data is among the strongest non-weight findings in the class.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

One concrete data point for the thread. With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most threads assume.

Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Report rather than reply if it drifts again.